Название продукции:3-((2-Chloropyridin-4-yl)oxy)-6-iodo-2-methylpyridine

IUPAC Name:3-[(2-chloropyridin-4-yl)oxy]-6-iodo-2-methylpyridine

CAS:1628184-06-4
Молекулярная формула:C11H8ClIN2O
Чистота:98%
Номер в каталоге:CM535948
Молекулярная масса:346.55

Упаковочная единица Доступно для заказа Цена ($) Количество
CM535948-100mg in stock ưŢǯ
CM535948-250mg in stock ŢưȎ
CM535948-1g in stock źŢȎ
CM535948-5g 1-2 Weeks ưŢǯƞ
CM535948-10g 1-2 Weeks ŢưȎŔ

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:1628184-06-4
Молекулярная формула:C11H8ClIN2O
Точка плавления:-
Smiles-код:CC1=NC(I)=CC=C1OC2=CC(Cl)=NC=C2
Плотность:
Номер в каталоге:CM535948
Молекулярная масса:346.55
Точка кипения:
Номер Mdl:
Хранение:Store at room temperature

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Vimseltinib
Vimseltinib (DCC-3014) is a potent and highly selective oral CSF1R kinase inhibitor that selectively and effectively inhibits CSF1R by utilizing the unique characteristics of the switch control region that regulates kinase conformational activation. The key phase 3 MOTION study conducted by vimseltinib in patients with giant cell tumor of the tendon sheath (TGCT) has shown positive results, and it is expected to submit a listing application to the FDA and the European Union next year.

Related Products